Key players include Entera Bio, Kalytera Therapeutics, Mesentech Inc., Isto Biologics, Medtronic plc, Regenexx, Sri Sri Holistic Hospital, and Huff Orthopaedics & Sports Medicine, among others.
The global non-union fractures market is being driven by the fracture fixation products industry, which is expected to grow at a CAGR of 7.5% in the forecast period of 2022-2027.
Non-union bone fracture is a changeless disappointment of recuperating following a broken bone unless intercession for example, surgery) is performed. Non-union fractures can be categorised into hypertrophic (generally due to mechanical failure/ callus formation) and atrophic (usually due to organic failure/ no callus and bone resorption). A delayed or non-union fracture forms a structural resemblance to a fibrous joint and is often called pseudoarthrosis. Non-union fracture is an objective complexity of a bone fracture and may happen when the bone moves excessively, has an inadequate blood supply or gets infected. Patients who smoke have a higher occurrence of non-union fractures.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Treatment via stem cell therapies is also on the rise, such as the Regenexx stem cell procedure. The explanations for a non-union fracture may comprise complicated, multisegmental fractures (severe comminution), open fractures, fractures associated with tumours (pathologic fractures), infection, inadequate fracture immobilisation (fixation), insufficient blood supply, poor nutrition, and chronic disease states (diabetes, renal failure, metabolic bone disease).
The increased occurrence of sports-related and mechanical injuries around the world is driving the market for non-union fractures. The market is further boosted by the world's expanding geriatric population. Pathologic fractures are more common in the ageing population, which is fuelling the market for non-union fractures. Other conditions that are driving demand for the product include diabetes, obesity, poor nutrition, and bone infection.
Entera Bio is a product-focused biotechnology company specialising in the oral delivery of large molecules and biologics. It is currently conducting clinical trials on its proprietary technology, allowing oral delivery of large molecules and biologics while enhancing their absorption in the GI tract. It's technology addresses the two major problems of oral drug delivery of extensive molecule APIs (active pharmaceutical ingredients). Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract and are rapidly degraded by many enzymes and acids in the gastrointestinal tract.
Headquarters: Novato, California, United States
Claritas Pharmaceuticals is an innovative biotech company developing R-107 for the treatment of vaccine-resistant COVID strains. Their scientific team has built a reputation for global leadership in basic science, drug development, and clinical medicine. Our expertise and professional network enable us to create groundbreaking opportunities that tackle drug development challenges.
Headquarters: Vancouver, British Columbia
Mesentech is a pre-clinical platform company developing drug-conjugates targeted to the bone. Its first product is a regenerative medicine product that targets mesenchymal stem cells with a potent (sub-nano-molar) prostaglandin mimetic that is released selectively in the bone resulting in bone regeneration. This drug can be used systemically to treat low-bone-density disorders or for local indications such as fracture-healing.
Headquarters: Hopkinton, Massachusetts, United States
Isto Biologics is an orthobiologics company dedicated for improving patient quality of life by using human biology science to advance spine, orthopaedics, and sports medicine solutions. Isto Biologics is focused on offering evidence-based solutions for bone regeneration and cell therapy to help improve patient outcomes. The company’s best-in-class product offerings include Arteriocyte’s market-leading Magellan® Autologous Platelet Separator and Isto’s bone-growth and cell-therapy products including InQu® Bone Graft Extender & Substitute; and Influx™, a natural bone-graft material.
Headquarters: Minneapolis, United States
Medtronic plc is an American Irish registered medical device company that primarily operates in the United States. The company develops and manufactures medical device technologies and therapies to treat chronic diseases worldwide. Medtronic has an operational and executive headquarters in Fridley, Minnesota, in the United States. In 2015, Medtronic acquired Irish–tax registered Covidien (United States tax inversion to Ireland from 2007), in the most significant United States corporate tax inversion in history, which enabled Medtronic to move its legal registration from the United States to Ireland. Medtronic operates in 140 countries and employs over 1,04,950 people.
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.